Demystifying IRA Drug Price Negotiation

  • This page as PDF


Avalere experts will explore the potential implications of the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program guidance and discuss implementation strategies for the near- and long-term.

As the Biden administration releases additional details about IRA policies, including the recent Center for Medicare and Medicaid Services (CMS) guidance on Medicare negotiation and maximum fair price (MFP), understanding these policies is critical as stakeholders prepare their business strategies and identify opportunities to shape policy development.

In this webinar, our experts provided insights and analysis on the current negotiation policies and their present and future impacts on healthcare manufacturers, providers, payers, and patients. We will cover topics including:

  • Key provisions of the Medicare drug price negotiation guidance released on March 15, including identification of selected drugs and the negotiation process for price applicability year (PY) 2026
  • Negotiation process and implementation considerations for manufacturers in the near- and long-term
  • Operationalizing maximum fair price (MFP) in Medicare Part D and its potential impact on net price and patient access
  • How drug price negotiation provisions will redefine product development, price setting, and indication sequencing moving forward


Our panel of experts provided recommendations on how healthcare stakeholders can prepare for drug price negotiation and adapt their strategy to position themselves for success.


Guest Speaker
Elizabeth Carpenter Moderator
Guest Speaker
Kelsey Lang
Guest Speaker
Shalini Parekh
Lisa Joldersma Strategic Advisor
From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Drug Pricing and Affordability
Please enter your email address to be notified when new Drug Pricing and Affordability insights are published.

Back To Top